Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Colorectal Neoplasms

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 77 articles:
HTML format



Single Articles


    September 2020
  1. DE GOOYER JM, Elekonawo FMK, Bos DL, van der Post RS, et al
    Multimodal CEA-targeted image-guided colorectal cancer surgery using 111In-labeled SGM-101.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-2255.
    PubMed     Abstract available


    July 2020
  2. KAWAZOE A, Kuboki Y, Shinozaki E, Hara H, et al
    Multicenter phase 1/2 Trial of napabucasin and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503/SCOOP Trial).
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1803.
    PubMed     Abstract available


  3. RANDON G, Pagani F, Pietrantonio F
    MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Response.
    Clin Cancer Res. 2020;26:3495.
    PubMed    


  4. OTTAIANO A, Caraglia M
    MGMT Promoter Methylation as a Target In Metastatic Colorectal Cancer: Rapid Turnover and Use of Folates Alter its Study-Letter.
    Clin Cancer Res. 2020;26:3493-3494.
    PubMed    


    June 2020
  5. CHU JE, Johnson B, Kugathasan L, Morris VK, et al
    Population-based screening for BRAF (V600E) in metastatic colorectal cancer reveals increased prevalence and poor prognosis.
    Clin Cancer Res. 2020 Jun 22. pii: 1078-0432.CCR-20-1024.
    PubMed     Abstract available


    May 2020
  6. VAYRYNEN JP, Lau MC, Haruki K, Vayrynen SA, et al
    Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin & eosin stained sections.
    Clin Cancer Res. 2020 May 21. pii: 1078-0432.CCR-20-0071.
    PubMed     Abstract available


  7. MCCUAIG S, Barras D, Mann E, Friedrich M, et al
    The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-1086.
    PubMed     Abstract available


    April 2020
  8. LAKINS MA, Koers A, Giambalvo R, Munoz-Olaya J, et al
    FS222, a CD137/PD-L1 tetravalent bispecific antibody exhibits low toxicity and anti-tumor activity in colorectal cancer models.
    Clin Cancer Res. 2020 Apr 28. pii: 1078-0432.CCR-19-2958.
    PubMed     Abstract available


  9. KIM RD, Azad NS, Morse MA, Poplin E, et al
    Phase II Study of Ensituximab, a Novel Chimeric Monoclonal Antibody, in Adults with Unresectable, Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Apr 17. pii: 1078-0432.CCR-20-0426.
    PubMed     Abstract available


  10. BRUUN J, Kryeziu K, Eide PW, Moosavi SH, et al
    Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity.
    Clin Cancer Res. 2020 Apr 16. pii: 1078-0432.CCR-19-3637.
    PubMed     Abstract available


  11. MORRIS VK, Bekaii-Saab T
    Improvements in Clinical Outcomes for BRAFV600E-mutant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-19-3809.
    PubMed     Abstract available


    March 2020
  12. MAX MA X, Bendell JC, Hurwitz HI, Ju C, et al
    Disease Monitoring Using Post-Induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer.
    Clin Cancer Res. 2020 Mar 27. pii: 1078-0432.CCR-19-1209.
    PubMed     Abstract available


    February 2020
  13. MIDDLETON G, Yang Y, Campbell CD, Andre T, et al
    BRAF-mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer.
    Clin Cancer Res. 2020 Feb 11. pii: 1078-0432.CCR-19-3579.
    PubMed     Abstract available


    November 2019
  14. PIETRANTONIO F, Lobefaro R, Antista M, Lonardi S, et al
    Capecitabine and temozolomide versus FOLFIRI in RAS mutated, MGMT methylated metastatic colorectal cancer.
    Clin Cancer Res. 2019 Nov 18. pii: 1078-0432.CCR-19-3024.
    PubMed     Abstract available


  15. DATTA J, Smith JJ, Chatila WK, McAuliffe JC, et al
    Co-Altered Ras/B-raf and TP53 is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Metastatic Colorectal Cancer Patients.
    Clin Cancer Res. 2019 Nov 12. pii: 1078-0432.CCR-19-2390.
    PubMed     Abstract available


    October 2019
  16. WANG S, Huang J, Li C, Zhao L, et al
    MAP9 loss triggers chromosomal instability, initiates colorectal tumorigenesis and is associated with poor survival of colorectal cancer patients.
    Clin Cancer Res. 2019 Oct 29. pii: 1078-0432.CCR-19-1611.
    PubMed     Abstract available


    September 2019
  17. YUAN C, Sato K, Hollis BW, Zhang S, et al
    Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance).
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-0877.
    PubMed     Abstract available


  18. YAEGER R, Kotani D, Mondaca S, Parikh AR, et al
    Response to Anti-EGFR Therapy in Patients with BRAF non-V600-Mutant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2019 Sep 12. pii: 1078-0432.CCR-19-2004.
    PubMed     Abstract available


  19. LLOSA NJ, Luber B, Tam AJ, Smith KN, et al
    Intratumoral Adaptive Immunosuppression and Type 17 Immunity in Mismatch Repair Proficient Colorectal Tumors.
    Clin Cancer Res. 2019;25:5250-5259.
    PubMed     Abstract available


    August 2019
  20. ANGELL HK, Bruni D, Barrett JC, Herbst R, et al
    The Immunoscore: Colon Cancer and Beyond.
    Clin Cancer Res. 2019 Aug 14. pii: 1078-0432.CCR-18-1851.
    PubMed     Abstract available


  21. LAZZARI L, Corti G, Picco G, Isella C, et al
    Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer.
    Clin Cancer Res. 2019 Aug 2. pii: 1078-0432.CCR-18-3440.
    PubMed     Abstract available


    July 2019
  22. LEE DW, Han SW, Bae JM, Jang H, et al
    Tumor Mutation Burden and Prognosis in Colorectal Cancer Patients Treated with Adjuvant Fluoropyrimidine and Oxaliplatin.
    Clin Cancer Res. 2019 Jul 8. pii: 1078-0432.CCR-19-1105.
    PubMed     Abstract available


  23. WILLIS JA, Overman MJ, Vilar E
    Mismatch repair-proficient colorectal cancer: finding the right TiME to respond.
    Clin Cancer Res. 2019 Jul 1. pii: 1078-0432.CCR-19-1447.
    PubMed     Abstract available


    June 2019
  24. LIEU CH, Golemis EA, Serebriiskii IG, Newberg JY, et al
    Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer.
    Clin Cancer Res. 2019 Jun 26. pii: 1078-0432.CCR-19-0899.
    PubMed     Abstract available


  25. FREIRE VALLS A, Knipper K, Giannakouri E, Sarachaga V, et al
    VEGFR1(+) metastasis-associated macrophages contribute to metastatic angiogenesis and influence colorectal cancer patient outcome.
    Clin Cancer Res. 2019 Jun 25. pii: 1078-0432.CCR-18-2123.
    PubMed     Abstract available


    April 2019
  26. PISKOL R, Huw LY, Sergin I, Klijn C, et al
    A Clinical Applicable Gene Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer.
    Clin Cancer Res. 2019 Apr 19. pii: 1078-0432.CCR-18-3032.
    PubMed     Abstract available


  27. FENG Q, Chang W, Mao Y, He G, et al
    Tumor-associated macrophages as prognostic and predictive biomarkers for postoperative adjuvant chemotherapy in patients with stage II colon cancer.
    Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-18-2076.
    PubMed     Abstract available


  28. WANG XC, Yue X, Zhang R, Liu TY, et al
    Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating non-homologous end joining repair.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3735.
    PubMed     Abstract available


  29. DIAZ-MAROTO NG, Sanz-Pamplona R, Berdiel-Acer M, Cimas FJ, et al
    Non-canonical TGFb pathway relieves the blockade of IL-1b/TGFb-mediated crosstalk between tumour and stroma: TGFBR1TAK1 inhibition in colorectal cancer.
    Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3957.
    PubMed     Abstract available


  30. SCHIRRIPA M, Biason P, Lonardi S, Pella N, et al
    Class 1, 2 and 3 BRAF mutated metastatic colorectal cancer: a detailed clinical, pathological and molecular characterization.
    Clin Cancer Res. 2019 Apr 9. pii: 1078-0432.CCR-19-0311.
    PubMed     Abstract available


  31. ANANDAPPA G, Lampis A, Cunningham D, Khan KH, et al
    MicroRNA 31-3p expression and benefit from anti-EGFR inhibitors in metastatic colorectal cancer patients enrolled in the prospective phase II PROSPECT-C trial.
    Clin Cancer Res. 2019 Apr 5. pii: 1078-0432.CCR-18-3769.
    PubMed     Abstract available


  32. MORRIS VK
    Circulating Tumor DNA in Advanced Anal Cancer: A Blood Biomarker Goes Viral.
    Clin Cancer Res. 2019;25:2030-2032.
    PubMed     Abstract available


    February 2019
  33. SIRAVEGNA G, Sartore-Bianchi A, Nagy RJ, Raghav K, et al
    Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer.
    Clin Cancer Res. 2019 Feb 26. pii: 1078-0432.CCR-18-3389.
    PubMed     Abstract available


    January 2019
  34. OGAWA R, Yamamoto T, Hirai H, Hanada K, et al
    Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via CXCL1/8-CXCR2 axis.
    Clin Cancer Res. 2019 Jan 31. pii: 1078-0432.CCR-18-3684.
    PubMed     Abstract available


  35. TOKUNAGA R, Xiu J, Johnston C, Goldberg RM, et al
    Molecular profiling of appendiceal adenocarcinoma and comparison with right-sided and left-sided colorectal cancer.
    Clin Cancer Res. 2019 Jan 28. pii: 1078-0432.CCR-18-3388.
    PubMed     Abstract available


    December 2018
  36. WASSERMAN I, Lee LH, Ogino S, Marco MR, et al
    SMAD4 loss in colorectal cancer patients correlates with recurrence, loss of immune infiltrate, and chemoresistance.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-1726.
    PubMed     Abstract available


  37. YANG W, Ma Y, Smith-Warner SA, Song M, et al
    Calcium intake and survival after colorectal cancer diagnosis.
    Clin Cancer Res. 2018 Dec 13. pii: 1078-0432.CCR-18-2965.
    PubMed     Abstract available


    November 2018
  38. PEETERS M, Price T, Boedigheimer M, Kim TW, et al
    Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Treated With Panitumumab in the ASPECCT Study.
    Clin Cancer Res. 2018 Nov 28. pii: 1078-0432.CCR-18-2072.
    PubMed     Abstract available


  39. PARK SY, Kim JY, Choi JH, Kim JH, et al
    Inhibition of LEF1-mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
    Clin Cancer Res. 2018 Nov 16. pii: 1078-0432.CCR-18-1232.
    PubMed     Abstract available


    October 2018
  40. LEE LY, Woolley CE, Starkey T, Biswas S, et al
    SERUM- AND GLUCOCORTICOID-INDUCED KINASE SGK1 DIRECTLY PROMOTES THE DIFFERENTIATION OF COLORECTAL CANCER CELLS AND RESTRAINS METASTASIS.
    Clin Cancer Res. 2018 Oct 15. pii: 1078-0432.CCR-18-1033.
    PubMed     Abstract available


    September 2018
  41. PARIKH AR, Lee FC, Yau L, Koh H, et al
    MAVERICC, a randomized, biomarker-stratified, phase 2 study of mFOLFOX6-bevacizumab vs FOLFIRI-bevacizumab as first-line chemotherapy in metastatic colorectal cancer.
    Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-1221.
    PubMed     Abstract available


    August 2018
  42. LAURENT-PUIG P, Grisoni ML, Heinemann V, Liebaert F, et al
    Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Aug 14. pii: 1078-0432.CCR-18-1324.
    PubMed     Abstract available


  43. LEE V, Wang JS, Zahurak ML, Gootjes EC, et al
    A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan.
    Clin Cancer Res. 2018 Aug 10. pii: 1078-0432.CCR-18-0421.
    PubMed     Abstract available


    June 2018
  44. PAAUWE M, Schoonderwoerd MJ, Helderman RFCPA, Harryvan TJ, et al
    Endoglin expression on cancer-associated fibroblasts regulates invasion and stimulates colorectal cancer metastasis.
    Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0329.
    PubMed     Abstract available


  45. GALLOIS C, Taieb J, Le Corre D, Le Malicot K, et al
    Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy.
    Clin Cancer Res. 2018 Jun 19. pii: 1078-0432.CCR-18-0866.
    PubMed     Abstract available


  46. BIAN Z, Zhang J, Li M, Feng Y, et al
    LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling.
    Clin Cancer Res. 2018 Jun 18. pii: 1078-0432.CCR-17-2967.
    PubMed     Abstract available


  47. KIM TW, Peeters M, Thomas AL, Gibbs P, et al
    Impact of Emergent Circulating Tumor DNA RAS Mutation in Panitumumab-Treated Chemoresistant Metastatic Colorectal Cancer.
    Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-17-3377.
    PubMed     Abstract available


    May 2018
  48. NODA M, Okayama H, Tachibana K, Sakamoto W, et al
    Glycosyltransferase gene expression identifies a poor prognostic colorectal cancer subtype associated with mismatch repair deficiency and incomplete glycan synthesis.
    Clin Cancer Res. 2018 May 29. pii: 1078-0432.CCR-17-3533.
    PubMed     Abstract available


  49. TOWNSEND A, Tebbutt NC, Karapetis CS, Cooper P, et al
    PHASE IB/II STUDY OF SECOND LINE THERAPY WITH PANITUMUMAB, IRINOTECAN AND EVEROLIMUS (PIE) IN KRAS WILD TYPE METASTATIC COLORECTAL CANCER.
    Clin Cancer Res. 2018 May 8. pii: 1078-0432.CCR-17-3590.
    PubMed     Abstract available


    April 2018
  50. RODRIGUEZ J, Vicent S, Chopitea A, Ponz-Sarvise M, et al
    Adjuvant therapy for colon cancer: genes, genes... and the patient in the center.
    Clin Cancer Res. 2018 Apr 20. pii: 1078-0432.CCR-18-0818.
    PubMed     Abstract available


    March 2018
  51. TOLEDO RA, Garralda E, Mitsi M, Pons T, et al
    Exome sequencing of plasma DNA portrays the mutation landscape of colorectal cancer and discovers mutated VEGFR2 receptors as modulators of anti-angiogenic therapies.
    Clin Cancer Res. 2018 Mar 27. pii: 1078-0432.CCR-18-0103.
    PubMed     Abstract available


  52. MURCIA O, Jover R, Egoavil CM, Juarez M, et al
    TFAP2E Methylation and Expression Status Does Not Predict Response to 5FU-based Chemotherapy in Colorectal Cancer.
    Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-2940.
    PubMed     Abstract available


  53. KANDIMALLA R, Gao F, Matsuyama T, Ishikawa T, et al
    Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-3236.
    PubMed     Abstract available


  54. HILL AG, Findlay M, Burge M, Jackson C, et al
    Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-0646.
    PubMed     Abstract available


    February 2018
  55. MESANGE P, Bouygues A, Ferrand N, Sabbah M, et al
    Combinations of Bevacizumab and Erlotinib show activity in colorectal cancer independent of RAS status.
    Clin Cancer Res. 2018 Feb 28. pii: 1078-0432.CCR-17-3187.
    PubMed     Abstract available


  56. HAYNES J, McKee TD, Haller AC, Wang Y, et al
    Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer.
    Clin Cancer Res. 2018 Feb 23. pii: 1078-0432.CCR-17-1715.
    PubMed     Abstract available


  57. LI X, Wang Q, Gao X, Yu T, et al
    REGgamma controls Hippo signaling and reciprocal NF-kappaB-YAP regulation to promote colon cancer.
    Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2986.
    PubMed     Abstract available


  58. LAMPRECHT S, Kaller M, Schmidt EM, Blaj C, et al
    PBX3 is part of an EMT regulatory network and indicates poor outcome in colorectal cancer.
    Clin Cancer Res. 2018 Feb 1. pii: 1078-0432.CCR-17-2572.
    PubMed     Abstract available


    January 2018

  59. Correction: Prevention of Colitis and Colitis-Associated Colorectal Cancer by a Novel Polypharmacological Histone Deacetylase Inhibitor.
    Clin Cancer Res. 2018;24:499.
    PubMed    


  60. MARSHALL JF
    Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?
    Clin Cancer Res. 2018;24:253-255.
    PubMed     Abstract available


    December 2017
  61. LIANG Q, Ma D, Zhu X, Wang Z, et al
    RING-finger protein 6 amplification activates JAK/STAT3 pathway by modifying SHP-1 ubiquitylation and associates with poor outcome in colorectal cancer.
    Clin Cancer Res. 2017 Dec 29. pii: 1078-0432.CCR-17-2133.
    PubMed     Abstract available


  62. DIENSTMANN R
    Tumor side as model of integrative molecular classification of colorectal cancer.
    Clin Cancer Res. 2017 Dec 21. pii: 1078-0432.CCR-17-3477.
    PubMed     Abstract available


  63. SVEEN A, Bruun J, Eide PW, Eilertsen IA, et al
    Colorectal cancer Consensus Molecular Subtypes translated to preclinical models uncover potentially targetable cancer-cell dependencies.
    Clin Cancer Res. 2017 Dec 14. pii: 1078-0432.CCR-17-1234.
    PubMed     Abstract available


  64. BERGER MD, Stintzing S, Heinemann V, Cao S, et al
    A polymorphism within the vitamin D transporter gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab or FOLFIRI/cetuximab.
    Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1663.
    PubMed     Abstract available


  65. ULINTZ PJ, Greenson JK, Wu R, Fearon ER, et al
    Lymph Node Metastases in Colon Cancer are Polyclonal.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-1425.
    PubMed     Abstract available


  66. CARNERO A, Lucena-Cacace A, Otero-Albiol D, Jimenez-Garcia MP, et al
    NAMPT is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and resistance to therapy through Sirt1 and PARP.
    Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2575.
    PubMed     Abstract available


    November 2017
  67. LOREE JM, Pereira AA, Lam M, Willauer AN, et al
    Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes.
    Clin Cancer Res. 2017 Nov 27. pii: 1078-0432.CCR-17-2484.
    PubMed     Abstract available


    October 2017
  68. GROTHEY A, Strosberg JR, Renfro LA, Hurwitz HI, et al
    A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Ontuxizumab (MORAb-004) in Patients with Chemorefractory Metastatic Colorectal Cancer.
    Clin Cancer Res. 2017 Oct 30. pii: clincanres.1558.2017.
    PubMed     Abstract available


  69. LAL N, White BS, Goussous G, Pickles OJ, et al
    KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer.
    Clin Cancer Res. 2017 Oct 23. pii: clincanres.1090.2017.
    PubMed     Abstract available


  70. BOCCACCIO C, Luraghi P, Bigatto V, Cipriano E, et al
    A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy.
    Clin Cancer Res. 2017 Oct 3. pii: clincanres.2151.2017.
    PubMed     Abstract available


    September 2017
  71. KANG DW, Lee BH, Suh YA, Choi YS, et al
    Phospholipase D1 inhibition linked to upregulation of ICAT blocks colorectal cancer growth hyperactivated by Wnt/beta-catenin and PI3K/Akt Signaling.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0749.2017.
    PubMed     Abstract available


  72. JOUNG JG, Oh BY, Hong HK, AlKhalidi H, et al
    Tumor heterogeneity predicts metastatic potential in colorectal cancer.
    Clin Cancer Res. 2017 Sep 22. pii: clincanres.0306.2017.
    PubMed     Abstract available


  73. YIN Y, Yao S, Hu Y, Feng Y, et al
    The Immune-microenvironment Confers Chemoresistance of Colorectal Cancer through Macrophage-derived IL-6.
    Clin Cancer Res. 2017 Sep 19. pii: clincanres.1283.2017.
    PubMed     Abstract available


  74. BARTOLOME RA, Aizpurua C, Jaen M, Torres S, et al
    Monoclonal antibodies directed against cadherin RGD exhibit therapeutic activity against melanoma and colorectal cancer metastasis.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1444.2017.
    PubMed     Abstract available


  75. JIAO HL, Ye YP, Yang RW, Sun HY, et al
    Down-regulation of SAFB sustains the NF-kappaB pathway by targeting TAK1 during the progression of colorectal cancer.
    Clin Cancer Res. 2017 Sep 14. pii: clincanres.0747.2017.
    PubMed     Abstract available


    March 2017
  76. PAKISH JB, Zhang Q, Chen Z, Liang H, et al
    Immune microenvironment in microsatellite instable endometrial cancers: Hereditary or sporadic origin matters.
    Clin Cancer Res. 2017 Mar 6. pii: clincanres.2655.2016.
    PubMed     Abstract available


  77. PICHLER M, Stiegelbauer V, Vychytilova-Faltejskova P, Ivan C, et al
    Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis.
    Clin Cancer Res. 2017;23:1323-1333.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: